CXCL12 and hepatocellular carcinoma: The results demonstrated that when CXCR4 was inhibited, the ability of CXCL12 protein or CAF supernatant to upregulate FOLR1 in HCC cells was inhibited, and the sensitivity of HCC cells to sorafenib was increased (Fig. 4j-k).